A5016103869- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Click Chemistry and Applications
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Neutropenia and Cancer Infections
- Fungal Infections and Studies
- Hemophilia Treatment and Research
- Antifungal resistance and susceptibility
Complejo Hospitalario de Salamanca
2002-2024
Centro de Investigación del Cáncer
2024
Universidad de Salamanca
2024
Instituto de Investigación Biomédica de Salamanca
2024
Hospital Virgen de la Concha
2017
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction asciminib may be promising option intolerant patients, as it is first-in-class inhibitor more selective mechanism action different from ATP-competitive inhibition that occurs Therefore, our goal was to analyze toxicities shown well study cross-toxicity previous (2) Methods: An observational,...
Patients with chronic myeloid leukemia (CML) who have failed conventional tyrosine kinase inhibitors (cTKIs) and asciminib constitute a complex group of patients few therapeutic options. A retrospective descriptive multicenter observational study was carried out including CML had presented failure to ≥ 2 cTKIs asciminib, received or were not candidates ponatinib. Of the 19 enrolled, 8 due intolerance 11 resistance. The most common strategy for intolerant initiate previously administered cTKI...
The advent of tyrosine kinase inhibitors (TKIs) has changed the natural history chronic myeloid leukemia (CML), and transformation from phase to blast (BP) is currently an uncommon situation. However, it one major remaining challenges in management this disease, as associated with dismal outcomes. We report case a 63-year-old woman CML poor response imatinib who progressed BP-CML, driven by acquisition t(8;21)(q22;q22)/